Project uptown Basel taking shape
A competence center for Industry 4.0 is being created on the former site of ABB. Private investors have contributed around half a million Swiss francs to the project. The foundation stone has now been officially laid.
Model of the Competence Center for Industry 4.0 (img. Fankhauser Arealentwicklungen)
The Schorenareal extends over an area of 70,000m2 and lies between the motorway and railway line, just a few hundred meters from Münchenstein station. For decades, it was home to manufacturing by ABB’s predecessor BBC. In 2016, the canton sold the site to Basel lawyer and investor Thomas Staehelin, President of the Chamber of Commerce of the two Basel cantons at the time. With uptown Basel AG, it is establishing a competence center for Industry 4.0. Construction began in March, with the foundation stone for phase one officially laid last Friday. The first building will offer lettable space of 25,000m2 over five floors, of which 70 percent has already leased, as site developer Hans-Jörg Fankhauser revealed in an article by the Basler Zeitung newspaper.
Around 500 million francs is being invested in the development by uptown Basel AG, which is expected to create approximately 2,000 jobs. With Axians and Bouygues, two major European technology companies are confirmed as moving to uptown. Cumulatively, they intend to offer 400 jobs at this site.
The economic director of Basel-Land Thomas Weber speaks of a renaissance for industry in the canton. “A quantum leap has been achieved with Staehelin’s project” he says in the newspaper article. “The historic potential of the site has been perfectly transformed for the future.”
The first building will be completed at the end of 2021. A further 10,000m2 of lettable space will follow down the line.
Share this article
You might also be interested in
A research project is investigating the improvement in the condition of patients who have been hospitalized due to COVID-19. docdok.health based in Basel is contributing the smartphone app for the project.Read More
The Allschwil-based pharmaceutical company Idorsia receives a payment of 45 million US dollars as part of an agreement with Neurocrine Biosciences and shall also be entitled to claim milestone payments in future. Neurocrine has exercised a licensing option for a drug developed by Idorsia to treat epilepsy..Read More
Roche has received Emergency Use Authorization in the USA for an antibody test in connection with the novel coronavirus. The tests are already being distributed around the world. In May, production capacities are to already be scaled up to the high double-digit million area.Read More
Basel is valued as a location for company headquarters. In a rating from the fDi Intelligence platform of the Financial Times, Basel achieves eighth place in Europe. No other Swiss city does better.Read More
The investment and innovation promotion agency Basel Area Business & Innovation, previously known as BaselArea.swiss, can look back on a successful year in 2019. In this regard, positive developments in the healthtech sector and in Switzerland Innovation Park Basel Area stand out.Read More
The University Hospital Basel is the first Swiss hospital to have treated two Covid-19 patients with the plasma from a patient who has recovered from the virus, which means that they are receiving the appropriate antibodies. This method is a potential therapeutic option.Read More
The Basel-based Botnar Research Center for Child Health is providing capital in the amount of 15 million Swiss francs to its four partner institutions. In this way, the University of Basel should be in a position to advance research into dealing with the coronavirus outbreak.Read More